Kornimate/medical-research-clean huggingface dataset:
oral contraceptives and asthma control

Conditions: Asthma; Regulatory T Cell Function

Summary: asthma is a chronic inflammatory disorder of the airways affecting approximately 15 million individuals in the u.s. the rate of asthma exacerbations among women is twice that of men after adolescence, and a large proportion of females with asthma report worsened asthma symptoms during different phases of the menstrual cycle. hormonal influences have been hypothesized to account for these differences. decreased peak flow rates and increased symptoms have been found in females during the premenstrual phase of the menstrual cycle when estrogen and progesterone levels are low. estrogen and progesterone have both been found to reduce smooth muscle contractility and increase bronchial smooth muscle relaxation. a perimenstrual shift toward a th2 (allergic) phenotype characterized by a decreased interferon-gamma to interleukin-10 ratio has been demonstrated in healthy women not using oral contraceptives compared to midcycle; however, the effect was blunted in healthy oral contraceptive pill users, implying hormonal modulation of the allergic phenotype. several case reports have demonstrated a therapeutic benefit of oral contraceptives in decreasing asthma exacerbations and corticosteroid requirements. human studies have demonstrated that estrogen decreases pro-inflammatory cytokine generation, neutrophil recruitment, and inhibits inducible nitric oxide synthase activity, which could lead to lower exhaled nitric oxide levels. the measurement of the fractional concentration of exhaled nitric oxide (feno) is a non-invasive method to assess airway inflammation in adults and children with asthma. the hypotheses of the current study are that women using oral contraceptives will have lower feno levels and better asthma control as assessed by the asthma control testtm during different phases of the menstrual cycle. this study may identify clinically important changes in feno levels and asthma control during the menstrual cycle and modification of these effects by oral contraceptive pills. this data may lead to future studies aimed at identifying therapeutic roles for hormones in asthma therapy in women.


Eligibility criteria:
inclusion criteria: * asthmatic * female * aged 18-45 * user of combination oral contraceptive pills or non-user of any hormonal contraception exclusion criteria: * smoker * other underlying lung disease (i.e., emphysema, cystic fibrosis, lung cancer) * user of oral contraceptives that are not combination (estrogen + progesterone) pills * user of non-oral hormonal contraception * have been treated in the prior 4 weeks with oral steroids * have had a respiratory infection in the prior 4 weeks * asthma under poor control at study entry * presence of severe asthma

Keywords: asthma exhaled nitric oxide asthma control test
proton pump inhibitor empirical treatment in management of outpatients with gastroesophageal reflux disease.

Conditions: Patients With Typical Symptoms of GERD (GERD Q >= 8)

Summary: china survey of proton pump inhibitor empirical treatment in management of outpatients with gastroesophageal reflux disease

to estimate the overall responder rate after 4 weeks of proton pump inhibitor empirical treatment this will be a multicenter prospective observational study carried out in china. investigator will collect data in a pre-specified case report form from the outpatient. informed consents will be needed. investigator will provide patient diary card to each patient for them to note down the symptom frequency every day. main data from each outpatient will include demographics, gerd q, symptom frequency and proton pump inhibitor empirical treatment. data from each outpatient will be collected on the screening day, 2 weeks and 4 weeks.

Eligibility criteria:
inclusion criteria: * female or male, and any race, age ≥ 18 years and≤ 65 outpatients. * gastroenterologists already prescribe ppi standard dose bid as empirical treatment. * gerdq≥8 * the subject will not have endoscopy within 4 weeks after enrolment. * ability to provide informed consent, adhere to the study visit schedule, and complete all study assessments and complete the patient diary by his/herself. exclusion criteria: * if participating in any interventional clinical trial. * patient with alarm symptom of oncology(weight loss, recurrent dysphagia, anemia, hematemesis, melena). * continuous application of nonsteroidal anti-inflammation drugs or acid suppressive drug within 2 weeks before screening. * the need for h2-receptor antagonists (h2ra) including cimetidine, ranitidine and famotidine or sucralfate, antacids, traditional chinese medicine and prokinetics during the upcoming 4 weeks (study duration). * previous gastroesophageal surgery. * upper gastrointestinal malignancy, achalasia, and esophageal spasm or stricture. * peptic ulcer * diabetes * cerebral vascular disease * zollinger-ellison syndrome * scleroderma * hiatus hernia women * pregnant or lactating women * any other subjects were not suitable to this study in the opinion of the investigator.

Keywords: proton pump inhibitor, gerd, gerd q
helicobacter pylori eradication to prevent gastric cancer

Conditions: Helicobacter Infections; Stomach Neoplasms

Summary: gastric cancer is the fourth most common type of cancer and the second leading cause of cancer-related death in the world. in china, more than 390,000 new patients are diagnosed with gastric cancer and more than 300,000 patients are killed by the terrible disease annually. although gastric cancer has a multifactorial etiology, infection with h. pylori is highly associated with gastric carcinogenesis. therefore, eradication of h. pylori infection appears to reduce the risk of gastric cancer. however, several recent controlled interventional trials by h. pylori eradication to prevent gastric cancer have yielded disappointing results. the exact effect of h.pylori eradication on prevention of gastric cancer is unclear up to now. to clarify this problem, the investigators conducted a prospective, randomized, double-blind, placebo-controlled, population-based study to determine whether h pylori eradication would reduce the incidence of gastric cancer in a high-risk population in china.


Eligibility criteria:
inclusion criteria: * healthy registered inhabitants from 10 villages in a high-risk county of gastric cancer in china * age 30-59 years * a willingness to participate in the study as indicated by written informed consent exclusion criteria: * severe concomitant illness (eg, severe hypertension, coronary heart disease, diabetes mellitus, stroke, asthma, liver cirrhosis, tuberculosis, infectious hepatitis, and cardiac, respiratory, hepatic, or renal insufficiency) * patients with epilepsy or severe mental illness * previous diagnosis of cancer * a history of esophageal or gastric surgery * drug abuse and drug dependence * allergic to omeprazole, amoxicillin, or clarithromycin * pregnant and lactating women * previous history of h pylori eradication treatment * a negative 13c-urea breath test (ubt) * a definite indication of h. pylori eradication (eg, gastric or duodenum ulcer) * dysplasia or carcinoma lesions are found in esophageal or gastric histopathological examination * other factors or conditions might influence the results of study

Keywords: helicobacter infections helicobacter pylori drug therapy precancerous conditions stomach neoplasms incidence
c-arm cone beam ct perfusion guided cerebrovascular interventions

Conditions: Acute Ischemic Stroke

Summary: the overarching objective of our proposal is to develop a one-stop-shop imaging using the available c-arm cone-beam computed tomography (cbct) data acquisition systems currently widely available worldwide in interventional angiography suites to enable acute ischemic stroke patients to be imaged, triaged, treated, and assessed using a single modality in one room.

this is an evaluation to determine the efficacy of the use of c-arm cbct with smart recon novel software for the rapid assessment of time-resolved cta and ct perfusion in the setting of ischemic cerebrovascular events. as a leading center for the treatment of cerebrovascular disease in the midwest as well as being one of the first comprehensive stroke centers in the united states we have a large potential patient group to assess. the pilot plan is to compare conventional ct/cta/ctp acquired during the clinical work up with c-arm cbct/cta/ctp acquired in the angiography suite at initiation of therapy. the c-arm cbct acquisition provides whole brain coverage (compared to only 8 cm brain coverage with conventional ct) with less radiation and higher resolution; the ct perfusion maps obtained using c-arm cbct and new reconstruction algorithms provides better perfusion maps.

Eligibility criteria:
inclusion criteria: 1. patients with acute ischemic stroke presenting within 8 hours of onset 2. patients that present with a large artery occlusion 3. adults 18 years of age or older. 4. women of childbearing potential must not be pregnant. 5. national institutes of health stroke scale (nihss) of \>5 6. no severe co-morbidities exclusion criteria: 1. women that are pregnant 2. history of severe renal disease (e.g. stage 4-5) 3. history of renal transplant

Keywords: stroke
high flow nasal cannula and conventional oxygen therapy in the postoperative management of patients with mild to moderate obstructive sleep apnea

Conditions: High Flow Nasal Cannula; Obstructive Sleep Apnea

Summary: this study aims to compare the effectiveness of conventional oxygen therapy oxygen and high-flow nasal cannula therapy on oxygen saturation (spo2), measuring number of spo2 drop \>4% of base line oxygen saturation (o2 desaturation index), length of the icu stay, and the need of use supplemental continuous positive airway pressure (cpap) support in any of the study groups in the postoperative icu setting.

in the surgical setting, patients with obstructive sleep apnea (osa) may have increased upper airway collapsibility affecting ventilation and increased sensitivity to sedation from anesthetics and opioids. surgical patients with osa have a high risk for postoperative complications, including cardiac events, hypoxemia, and transfer to the intensive care unit . continuous positive airway pressure (cpap) is the gold standard treatment for moderate to severe osa , and effectively reduces the risk of cardiovascular events. evidence has shown that cpap effectively reduces length of icu stay (los) in the postoperative setting. in these scenarios, conventional oxygen therapy and high-flow nasal cannula (hfnc) therapy have been used as an alternative for cpap non-adherent patients. hfnc delivers warm, humidified air through a nasal cannula at high flow rates of up to 60 l/min. this high flow rate may increase end-expiratory pharyngeal pressure up to 3 cm h2o, decreasing the force required to alleviate airway collapse . using a nasal cannula interface in contrast to the cpap mask may provide a more comfortable experience for patients during sleep .

Eligibility criteria:
inclusion criteria: * age group from 21 - 40 years old. * both sexes. * mild to moderate obstructive sleep apnea (osa) patients with stop-bang score less than 5. * osa patients undergoing non cardiac surgeries. * patients who will undergo scheduled elective surgeries under general anesthesia. exclusion criteria: * patient refusal of procedure or participation in the study. * patients with severe osa, stop-bang score more than or equal 5. * patients dependent on home ventilation cpap or bilevel devices. * pregnant females. * post cardiac or thoracic surgery patients. * more than american society of anesthesiologists (asa) ii patients. * head and face trauma patients.
total shoulder replacement outcomes with autologous bone graft as fixator for glenoid anchor peg.

Conditions: Arthritis

Summary: we hypothesize that there will be a low incidence of glenoid loosening with a total shoulder arthroplasty using an anchor peg glenoid and autologous bone grafting. in addition, we suggest that the absence of radiolucent lines will correlate with excellent shoulder function.

this will be five year follow-up of glenoid anchor peg component fixation utilizing autologous bone graft in total shoulder arthroplasty. the purpose of this study is to investigate if the use of autologous bone graft around the anchor peg glenoid prosthesis correlates with better shoulder function. subjects having had this surgery who are five years or more out from surgery will have computed tomography and three plain radiographs to monitor for bony apposition, radiolucent lines and component loosening. these testings are not a study intervention and are for monitoring purposes.

Eligibility criteria:
inclusion criteria: - have had a total shoulder replacement with an anchor peg glenoid and autologous bone grafting at the department of orthopaedic surgery at university of nebraska and the nebraska medical center five years or longer ago. exclusion criteria: * unable to comprehend the consent form information * pregnant women

Keywords: total shoulder arthroplasty glenoid anchor peg component fixation autologous bone grafting
clinical utility of a non endoscopic device esocheck and biomarker esoguard as alternative to endoscopy for screening for barrett's esophagus in at risk population

Conditions: Barrett Esophagus

Summary: this will be a prospective randomized, controlled, virtual, patient study to measure the impact of esocheck/esoguard on health care provider's decision for upper endoscopy referral. the participants will complete two rounds of questions concerning the assessed risk for be and decision for endoscopy referral of 6 patient cases (clinical vignettes). after the first round has been completed, an esocheck/esoguard educational information package and the second round of 6 clinical vignettes including esoguard results will be sent.

this will be a prospective randomized, controlled, virtual, patient study to measure the impact of esocheck/esoguard on health care provider's decision for upper endoscopy referral. around 200 us physicians will be asked to participate in this study and at least 100 will be enrolled. physicians eligible for participation are those whose scope of practice includes preventative care and disease screening - namely screening of be, such as primary care physicians, family medicine physicians, and general practitioners; physicians whose scope of practice include diagnosis and management of esophageal disease may also participate. the participants will complete two rounds of questions concerning the assessed risk for be and decision for endoscopy referral of 6 patient cases (clinical vignettes). per round, there will be 3 different questionnaires consisting of 6 clinical vignettes (a/b/c). participants will be randomized to questionnaire a, b or c according to the randomization scheme. after the first round has been completed, an esocheck/esoguard educational information package and the second round of 6 clinical vignettes including esoguard results will be sent.

Eligibility criteria:
inclusion criteria: 1. board-certified physicians whose scope of practice includes preventative care and disease screening, and/or those whose scope of practice include diagnosis and management of esophageal disease (examples include but are not limited to primary care physicians/ general practitioners, family medicine physicians, gastroenterologists, and foregut surgeons); 2. have between 1 to 40 years of post-residency clinical experience within their field of practice; 3. have an active panel (whether as part of a group practice, or individually) of over 1000 patients with an adult patient load of more than 50%. exclusion criteria: * none
a to z study follow-up: collection of dna data from buccal swabs

Conditions: Weight Management; Diet Conditions; Dietary Recommendations; Overweight Management; Obesity

Summary: the goal of this study is to determine the association between genotypes and diet. the weight and weight loss data are already available from the previously completed study called: a to z study - benefits and risks of alternative weight loss strategies - a clinical trial, which was performed from 2003-2005 at stanford university. in the present study, interleukin genetics will obtain dna samples from the previously enrolled study subjects to investigate genetic influence of the response to macronutrient compositions of low caloric diets to weight loss.

interleukin genetics has derived, through an extensive search of the scientific literature, a genetic test panel in the area of weight management (wm), which includes the genes that have been shown to affect body weight. these genes have been associated with elevated risk for obesity.

Eligibility criteria:
inclusion criteria: * bmi (body mass index): 27-40 kg/m2 * gender: women only * age: 25-50 * menopausal status: pre-menopausal * weight stable for last 2-months * not on a weight loss plan * no ethnic restrictions * no plans to move from the area over the next 6-months * willing to accept random assignment * possess english speaking and reading skills to understand and complete forms such as informed consent and study evaluation exclusion criteria: * hypertension * diabetes (type 1 or 2) or history of gestational diabetes * heart disease diagnosis * renal or lever disease * active neoplasms * pregnant, lactating, within 6-months of birth, or planning to become pregnant in the next 6-months * hyperthyroidism, unless treated and under control * medications known to affect weight / energy expenditure * excessive alcohol intake (self-reported, \> 3 drinks/day) * postmenopausal, including surgical menopause * currently under psychiatric care, or severely clinically depressed (\>17 on beck inventory)

Keywords: genetic biomarker biomarker molecular diagnostics genes genetics overweight management weight management weight reduction snps single nucleotide polymorphisms
a study of the potential risk factors linked to the development of severe forms of endometriosis

Conditions: Endometriosis

Summary: this study will aim to identify genetic, medical, dietary and environmental factors associated with the development of endometrioma and/or deep infiltrating endometriosis in order to move towards early diagnosis and implementation of potential preventative measures.


Eligibility criteria:
inclusion criteria: * the subject is a female aged between 18 and 41 years * the subject has undergone a laparoscopy or laparotomy for a benign gynecological indication excluding pregnancy, in the last 3 months * the subject's surgery showed either no visible endometriosis lesions or histologically confirmed endometriosis lesions: superficial endometriosis, endometrioma or deep infiltrating endometriosis * the subject has given a written informed consent prior to any study-related procedures exclusion criteria: * the subject is pregnant * the subject's surgery results showed evidence of malignancy * the subject has a mental condition rendering her unable to understand the nature, scope and possible consequences of the study, and/or with evidence of an uncooperative attitude
effectiveness of pediatric intubation

Conditions: Cardiac Arrest

Summary: we hypothesized that the venner videolaryngoscope (a.p. advance™) is beneficial for intubation of pediatric manikins while performing cpr. in the current study, we compared effectiveness of the venner videolaryngoscope (a.p. advance™) and mil laryngoscopes in child resuscitation with and without cc.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * minimum 1 year of work experience in nursing exclusion criteria: * not meet the above criteria * wrist or low back diseases

Keywords: intubation
rituximab in adult acquired idiopathic thrombotic thrombocytopenic purpura

Conditions: Thrombotic Thrombocytopenic Purpura

Summary: multicentric non-randomized phase ii opened prospective study (10 centres involved). primary endpoint: * to evaluate the kinetics of b-cell depletion by rituximab and its pharmacokinetics in patients treated with rituximab in association with plasma exchanges. secondary endpoints: * to evaluate the tolerance of rituximab, the volume of plasma and the number of plasma exchange sessions required to achieve a durable complete remission, and to determinate the duration of b-cell depletion. * to evaluate the incidence of persistent severe acquired adamts13 deficiency following treatment with rituximab, as well as the incidence of relapses.

duration of the study: 3 years and 2 months, including 1 year of inclusion and 2 years of participation for the patient. experimental plan: patients fulfilling the inclusion criteria of the study will be treated according to the recommendations of the reference centre for the management of thrombotic microangiopathies. if patients present refractory ttp, infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.on diagnosis, during treatment and after remission achievement, the following values will be explored: adamts13 activity, adamts13 inhibitors and anti-adamts13 antibodies, b-cell lymphocytes quantification by immunophenotyping, and serum gammaglobulin level by serum protein electrophoresis. rituximab will also be quantified. number of patients: each participating centre may recruit and include 1 patient/year.amongst 10 participating centres, a total number of 10 patients should be included. specific activities during the study: three infusions of rituximab (375 mg/m2 /infusion), immediately after plasma exchange sessions on day 1, 4 and 15. blood samplings at day 1, 4 and 15, at 1 month and then every 3 month until month 24. expected results and perspectives: this study should provide evidence as to whether the association of rituximab to plasma exchanges allo an efficient b-cell depletion. if yes, a randomized study should be performed to evaluate the role of rituximab at the acute phase of acquired idiopathic ttp, immediately after the diagnosis was established.

Eligibility criteria:
inclusion criteria: * microangiopathic hemolytic anemia (\< 12 g/dl) with thrombocytopenia \<50 g/l, and mild or no renal failure (serum creatinine \< 150 µmol/l), * negative beta hcg and ongoing contraception during treatment and during the 24 months following the last infusion of rituximab, * refractory ttp (after 4 days of standard treatment) * \> 18 year old * and signed written informed consent. exclusion criteria: * hemolytic uremic syndrome (platelet count ³ 50 g/l and serum creatinine ³ 150 micromol/l), * ttp associated with another condition (hiv infection, cancer and/or chemotherapy, transplantation), * previous treatment with vincristine or cyclophosphamide or other immunomodulatory drugs (except steroids), within 2 months before inclusion ; * ongoing or planned pregnancy, lactation